Israel sees probable link between Pfizer-BioNTech vaccine and myocarditis cases
Both Canadian and Israeli health authorities say vaccine benefits outweigh risks
Israel's Health Ministry said on Tuesday it found the small number of heart inflammation cases observed mainly in young men who received Pfizer-BioNTech's COVID-19 vaccine in Israel were likely linked to their vaccination.
Pfizer has said it has not observed a higher rate of the condition, known as myocarditis, than would normally be expected in the general population.
In Israel, 275 cases of myocarditis were reported between December 2020 and May 2021 among more than five million vaccinated people, the ministry said in disclosing the findings of a study it commissioned to examine the matter.
Most patients who experienced heart inflammation spent no more than four days in the hospital and 95 per cent of the cases were classified as mild, according to the study, which the ministry said was conducted by three teams of experts.
The study found "there is a probable link between receiving the second dose (of Pfizer) vaccine and the appearance of myocarditis among men aged 16 to 30."
According to the findings, such a link was observed more among men aged 16 to 19 than in other age groups.
Causal link not established, Pfizer says
Pfizer said in a statement that it is aware of the Israeli observations of myocarditis, noting that no causal link to its vaccine has been established.
Adverse events are thoroughly reviewed and Pfizer meets regularly with the Vaccine Safety Department of the Israeli Ministry of Health to review data, it said.
Israel had held off making its 12- to 15-year-old population eligible for the vaccines, pending the Health Ministry report. In parallel to publishing those findings, a ministry committee approved vaccinating the adolescents, a senior official said.
"The committee gave the green light for vaccinating 12- to 15-year-olds, and this will be possible as of next week," Nachman Ash, Israel's pandemic-response co-ordinator, told Radio 103 FM. "The efficacy of the vaccine outweighs the risk."
Canadian government agrees benefits outweigh risks
In an email to CBC News on Wednesday, the Public Health Agency of Canada and Health Canada said they were monitoring international reports of myocarditis, but that "the benefits of vaccines authorized in Canada continue to outweigh the risks."
In addition, PHAC and Health Canada said that based on domestic reports, "Canada is not seeing higher rates [of myocarditis] than would be expected in the general population (outside of a vaccine context)."
"Health Canada, PHAC, and the provincial and territorial health authorities are aware of these cases and will continue to monitor closely."
A U.S. Centers for Disease Control and Prevention advisory group last month recommended further study of the possibility of a link between myocarditis and mRNA vaccines, which include those from Pfizer and Moderna.
CDC monitoring systems had not found more cases than would be expected in the population, but the advisory group said in a statement that members felt health-care providers should be made aware of reports of a "potential adverse event."
Israel has been a world leader in its vaccination rollout.
With COVID-19 infections down to just a handful a day and total active cases at just 340 across the country, the economy has fully opened, though restrictions remain on incoming tourism.
As of Tuesday, restrictions on social distancing and the need for special green vaccination passes to enter certain restaurants and venues were scrapped.
With files from CBC News